The aim of this study was to investigate whether 18F‑DCFPyL PET/CT imaging resulted in a change of decision on treatment management in patients with biochemically recurrent (BCR) prostate cancer. 253 patients with BCR prostate cancer who underwent restaging 18F‑DCFPyL PET/CT were assessed. Two urologists formulated a preferred treatment for each patient before and after knowing the results of the 18F‑DCFPyL PET/CT. In 103/253 cases (40.7%), a preferred treatment change based on the 18F‑DCFPyL PET/CT findings was reported. A positive 18F‑DCFPyL PET/CT (p < 0.001), and positive pathological lymph node status (pN1; p = 0.024) were significant predictors for an intended change of management, whereas a positive surgical margin (p = 0.022) was inversely associated with an intended change of management. It was concluded that, in this study, we found a significant impact of 18F‑DCFPyL PET/CT on the intended management of patients with BCR prostate cancer.
|Translated title of the contribution||Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study|
|Journal||Tijdschrift voor Urologie|
|Early online date||2021|
|Publication status||E-pub ahead of print - 2021|